Raymond James Financial Services Advisors
LXRX icon

Raymond James Financial Services Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-14,351
Closed -$60K – 2681
2019
Q4 		$60K Buy
+14,351
New +$55.2K ﹤0.01% 2752

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Pictet Asset Management (UK)
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Raymond James Financial Services Advisors's LXRX Position: Q1 2020 in Review

Raymond James Financial Services Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2020, closing a stake of 14,351 shares — an estimated $60K sold.

Raymond James Financial Services Advisors first reported a position in LXRX in Q4 2019 and held it in 1 quarter. The position peaked at $60K in Q4 2019. 113 funds tracked by Wall St. Rank hold LXRX as of Q1 2020.

  • Raymond James Financial Services Advisors reported no remaining Lexicon Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 14,351 Lexicon Pharmaceuticals shares in Q1 2020, an estimated $60K.
  • Raymond James Financial Services Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Lexicon Pharmaceuticals position peaked at $60K in Q4 2019.
  • 113 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2020, filed 21 Apr 2020.